cím účinkům) a nastavení referenčních rozmezí je často teprve úkolem do budoucnosti.

Závěr

Terapeutické monitorování léčiv bývá označováno jako „klíč" personalizované farmakoterapie řady onemocnění. Jedná se o specifickou metodu oboru klinická farmakologie, jejímž základním předpokladem je existence užšího vztahu mezi farmakologickým účinkem léčiva a jeho koncentrací v organismu než s jeho dávkou. Správně provedené TDM pomůže pomocí stanovení koncentrace léčiva v krvi následované erudovanou interpretací klinickým farmakologem (případně farmaceutem) a zpětnou vazbou s indikujícím klinikem nastavit optimální dávku léčiva u konkrétního pacienta, což umožní racionalizaci farmakoterapie s minimalizací rizika výskytu nežádoucích účinků, snížení mortality i morbidity, snížení nákladů na léčebnou péči a zejména zlepšení kvality života pacienta.

LITERATURA

1. Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol 2013; 69(1): 25–32.
2. Grundmann M, Kacířová I. Význam TDM, fenotypizace a genotypizace pro správné dávkování léčiv. Čas Lék čes 2010; 149: 482–487.
3. Dave V, Yadav RB, Yadav S, Sharma S, Sahu RK, Ajayi AF. A critique of computer simulation software's used in pharmacokinetics and pharmacodynamics analysis. Curr Clin Pharmacol 2018; 13(4): 216–235.
4. Kacířová I, Grundmann M. TDM antibiotik v klinické praxi. Kardiol Rev Int Med 2015; 17(1): 57–64.
5. Kacířová I, Grundmann M. Terapeutické monitorování amikacinu a gentamicinu v rutinní klinické praxi. Vnitř Lék 2015; 61(1): 33–41.
6. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper [published online ahead of print, 2020 May 7]. Intensive Care Med 2020; 1–27.
7. Suchánková H, Matušková Z, Vanduchová A. Terapeutické monitorování beta-laktamových antibiotik. Klin mikrobiol inf lék 2017; 23(1): 4–9.
8. Ben Romdhane H, Ben Fredj N, Chaabane A, et al. Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrol Ther 2019; 15(2): 110–114.
9. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations:V. Aminoglycosides. Pediatr Pulmonol 2013; 48: 1047–1061.
10. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41(6): 441–449.
11. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–99.
12. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013; 36(4): 217–230.
13. Alqahtani S, Alhumoud A, Abushomi H, Alsultan A, Balkhi B. Appropriate therapeutic drug monitoring of antibiotics contributed to lower nephrotoxicity. Int J Clin Pharmacol Ther 2020 Feb; 58(2): 82–88.
14. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 63(5): 1050–1057.
15. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925–942.
16. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49(3): 325–327.
17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011; 52(3): 285–292.
18. Helgason KO, Thomson AH, Ferguson C. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J Antimicrob Chemother 2008; 61(6): 1398–1399.
19. Abdul-Aziz MH, Lipman J, Roberts JA. Identifying „at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. Crit Care 2017; 21: 21(1): 283.
20. Roberts JA, Paul SK, Akova M, et al. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β--Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clin Infect Dis 2014; 58(8): 1072–1083.
21. Delattre IK, Taccone FS, Jacobs F, et al. Optimizing β--lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? Expert Rev Anti Infect Ther 2017; 15(7): 677–688.
22. Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit 2018; 40(5): 526–548.
23. Grundmann M, Kacířová I. Terapeutické monitorování hladin antiepileptik I. – obecné zásady, „stará" antiepileptika. Klin Farmakol Farm 2016; 30(2): 9–15.
24. Kacířová I, Grundmann M. Terapeutické monitorování hladin antiepileptik II. - „nová" antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16–22.
25. Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther 2018; 12: 271–280.
26. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1–02): 9–62.
27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–533.
28. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871–878.
29. Ahmed A, Waagstein F, Pitt B, et al. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol 2009; 103(1): 82–87.
30. Grundmann M, Kacířová I. Personalizovaná farmakoterapie digoxinem. Vnitř Lék 2015; 61(5): 406–409.
31. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol 2018; 13; 71(10): 1063–1074.
32. Moffett BS, Garner A, Zapata T, Orcutt J, Niu M, Lopez KN. Serum digoxin concentrations and clinical signs and symptoms of digoxin toxicity in the paediatric population. Cardiol Young 2016; 26: 498–493.
33. Park M. Congestive heart failure. In: Park MK, (ed) Pediatric Cardiology for Practitioners, (4th ed) St Louis: Mosby; 2002: 403–406.
34. Gabarin N, Jaeggi ET, Spears DA, Sermer M, Silversides CK, Bhagra CJ. Concurrent maternal and fetal tachyarrhythmia in pregnancy. Obstet Med 2017; 10(4): 195–197.
35. Grundmann M, Koristkova B, Brozmanova H, Kacirova I, Komzakova I. The interaction between digoxin and amiodarone during routine TDM. Ther Drug Monit 2005; 27(2): 219–220.
36. Hrudikova Vyskocilova E, Grundmann M, Duricova J, Kacirova I. Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017 Jun; 161(2): 134–143.
37. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 2017 Dec; 45(6): 737–779.
38. Stott KE, Hope WW. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother 2017; 72: i12–i18.
39. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018 May; 24 Suppl 1: e1–e38.
40. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST--AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect 2012; 18: E248–250.
41. Yi WM, Schoeppler KE, Jaeger J, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017 Sep 11; 16(1): 60.
42. Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management. Transplant Rev (Orlando) 2015; 29: 78–84.
43. Snanoudj R, Rabant M, Royal V, Pallet N, Noel LH, Legendre C. Nephrotoxicite des inhibiteurs de la calcineurine: presentation, problemes diagnostiques et facteurs de risques (Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors). Nephrol Ther 2009; 5(Suppl 6): S365–370.
44. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002; 41(2): 115–135.
45. Viklický O. Imunosuprese po transplantaci ledviny. Klinická farmakologie a farmacie. 2010; 24(2): 98–102.
46. Konsenzus IKEM; https://www2.ikem.cz/plm_lp/HVEZDAADCG.htm; 6. 2. 2020.
47. Teřl M, Čáp P, Dvořáková R, et al. Doporučený postup diagnostiky a léčby bronchiálního astmatu. Semily: GEUM; 2015.
48. http://www.sukl.cz/modules/medication/search.php; 4. 2. 2020.
49. Cooney L, Hawcutt D, Sinha I. The Evidence for Intravenous Theophylline Levels between 10–20 mg/L in Children Suffering an Acute Exacerbation of Asthma: A Systematic Review. PLoS One 2016 Apr 20; 11(4): e0153877.